Post-licensure safety of respiratory syncytial virus vaccines, Vaccine Adverse Event Reporting System, United States, May 2023–December 2024
Objective: Respiratory syncytial virus (RSV) vaccines, including Arexvy and Abrysvo, received approval in May 2023. The study aims to review the post-licensure safety of RSV vaccines by investigating adverse events using the Vaccine Adverse Event Reporting System (VAERS). Methods: We included VAERS...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Preventive Medicine Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211335525001895 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|